Discordant indolent BMI in patients with DLBCL
| Reference . | # of patients with any lymphomatous BMI (%) . | # of patients with discordant BMI (%) . | Treatment . | Prognostic significance of discordant vs concordant disease . |
|---|---|---|---|---|
| 25 | 22 (28%) | 11 (14%) | CHOP, CVP, M-BACOD, and MACOP-B | 2 y OS of 36% in discordant disease vs 11% in concordant disease |
| 4 | 43 (29%)* | 21 (14%)* | Chlorambucil/vincristine/prednisone, or CAP-BOP | Superior OS with discordant disease compared with concordant disease (P = .05) |
| 22 | 50 (N/A) | 19 (N/A) | Anthracycline-based regimens | 5 y OS of 79% with discordant disease vs 12% with concordant disease (P = .002) |
| 19 | 20 (34%) | 14 (24%) | proMACE/MOPP, proMACE/cytaBOM, CHOP, CVP, M-BACOD, and COMLA | Mean OS of 47.7 mo in discordant disease vs 13.1 mo in concordant disease (P < .05) |
| 23 | N/A | 21 (N/A) | Unknown chemotherapy regimens ± radiation therapy | Not assessed |
| 32 | 72 (16%) | 18 (4%) | Not described | Not assessed |
| 20 | 47 (27%) | 34 (20%) | CHOP or CHOP-like regimens | Superior PFS and OS with discordant disease compared with concordant disease (P = .055 and .05, respectively) |
| 1 | 55 (11%) | 26 (5%) | CHOP or CHOP-like regimens | 5 y OS of 62% with discordant disease vs 10% with concordant disease (multivariate P = .002) |
| 2 | 125 (16%) | 58 (7%) | R-CHOP | 3 y PFS of 56% in discordant disease vs 37% in concordant disease (multivariate P < .001); 3 y OS of 69% in discordant disease vs 49% in concordant disease (multivariate P = .007)† |
| 21 | 80 (13%) | 32 (5%) | R-CHOP | 3 y PFS of 57% in discordant disease vs 30% in concordant disease (multivariate P < .001); 3 y OS of 64% in discordant disease vs 39% in concordant disease (multivariate P = .011)† |
| Reference . | # of patients with any lymphomatous BMI (%) . | # of patients with discordant BMI (%) . | Treatment . | Prognostic significance of discordant vs concordant disease . |
|---|---|---|---|---|
| 25 | 22 (28%) | 11 (14%) | CHOP, CVP, M-BACOD, and MACOP-B | 2 y OS of 36% in discordant disease vs 11% in concordant disease |
| 4 | 43 (29%)* | 21 (14%)* | Chlorambucil/vincristine/prednisone, or CAP-BOP | Superior OS with discordant disease compared with concordant disease (P = .05) |
| 22 | 50 (N/A) | 19 (N/A) | Anthracycline-based regimens | 5 y OS of 79% with discordant disease vs 12% with concordant disease (P = .002) |
| 19 | 20 (34%) | 14 (24%) | proMACE/MOPP, proMACE/cytaBOM, CHOP, CVP, M-BACOD, and COMLA | Mean OS of 47.7 mo in discordant disease vs 13.1 mo in concordant disease (P < .05) |
| 23 | N/A | 21 (N/A) | Unknown chemotherapy regimens ± radiation therapy | Not assessed |
| 32 | 72 (16%) | 18 (4%) | Not described | Not assessed |
| 20 | 47 (27%) | 34 (20%) | CHOP or CHOP-like regimens | Superior PFS and OS with discordant disease compared with concordant disease (P = .055 and .05, respectively) |
| 1 | 55 (11%) | 26 (5%) | CHOP or CHOP-like regimens | 5 y OS of 62% with discordant disease vs 10% with concordant disease (multivariate P = .002) |
| 2 | 125 (16%) | 58 (7%) | R-CHOP | 3 y PFS of 56% in discordant disease vs 37% in concordant disease (multivariate P < .001); 3 y OS of 69% in discordant disease vs 49% in concordant disease (multivariate P = .007)† |
| 21 | 80 (13%) | 32 (5%) | R-CHOP | 3 y PFS of 57% in discordant disease vs 30% in concordant disease (multivariate P < .001); 3 y OS of 64% in discordant disease vs 39% in concordant disease (multivariate P = .011)† |
CAP-BOP, cyclophosphamide-doxorubicin-procarbazine-bleomycin-vincristine-prednisone; COMLA, cyclophosphamide-vincristine-methotrexate-cytosine-arabinoside-leucovorin; CVP, cyclophosphamide-vincristine-prednisone; M-BACOD, methotrexate-bleomycin-doxorubicin-cyclophosphamide-vincristine-dexamethasone; MACOP-B, methotrexate-doxorubicin-cyclophosphamide-vincristine-prednisone-bleomycin; N/A, not applicable or data not reported; OS, overall survival; PFS, progression-free survival; proMACE/CytaBOM, cyclophosphamide-doxorubicin-etoposide-cytarabine-bleomycin-vincristine-methotrexate-leucovorin-trimethoprim-sulfamethoxazole; proMACE/MOPP, prednisone-methotrexate-leucovorin-doxorubicin-cyclophosphamide-etoposide.
For LN histology both DLBCL and immunoblastic lymphoma were included.
Result controlled for IPI.